Eric Thomsen
Family Medicine · Beatrice, NENPI 1659374437
Payments from drug & device makers
Across 113 payments — averaging $29.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$659
- Boehringer Ingelheim$360
- AstraZeneca$297
- Bayer$278
- Pfizer$256
- Biohaven Pharmaceutical Holding Company Ltd.$210
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$1254%
- Food & beverage$3,26196%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $659 |
| Boehringer Ingelheim | 10 | $360 |
| AstraZeneca | 6 | $297 |
| Bayer | 4 | $278 |
| Pfizer | 10 | $256 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $210 |
| Lilly USA, LLC | 8 | $204 |
| Novo Nordisk | 8 | $168 |
| Amgen | 9 | $167 |
| Johnson & Johnson | 6 | $158 |
| Sanofi | 1 | $125 |
| Novartis | 6 | $94 |
| Kowa Pharmaceuticals America, Inc. | 7 | $91 |
| E.r. Squibb & Sons, L.L.C. | 3 | $90 |
| Merck | 4 | $60 |
| Boston Scientific | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Abbott | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| GSK | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$249
- NURTEC ODT$126
- MULTAQ$125
- UBRELVY$125
- QULIPTA$125
How this compares
$3,386 in reported general payments places this provider in the 85th percentile of 981 family medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 137 | $91,457 |
| EliquisApixaban | 130 | $76,044 |
| JardianceEmpagliflozin | 97 | $67,676 |
| TrulicityDulaglutide | 50 | $54,921 |
| FarxigaDapagliflozin Propanediol | 83 | $51,025 |
| OzempicSemaglutide | 29 | $30,544 |
| MounjaroTirzepatide | 21 | $22,248 |
| UbrelvyUbrogepant | 17 | $17,713 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $10,236 |
| KerendiaFinerenone | 17 | $10,170 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $7,359 |
| InvokametCanagliflozin/Metformin Hcl | 12 | $6,901 |
| LinzessLinaclotide | 12 | $6,532 |
| Benicar HctOlmesartan/Hydrochlorothiazide | 12 | $4,943 |
| Telmisartan | 195 | $4,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto, Invokamet | $158 | $98,358149 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $360 | $78,398121 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $204 | $77,16971 claims |
| PfizerEliquis | $256 | $76,044130 claims |
| AstraZenecaFarxiga, Symbicort, Crestor | $297 | $56,682114 claims |
| Novo NordiskOzempic | $168 | $30,54429 claims |
| AbbVieUbrelvy, Linzess, Synthroid | $659 | $25,76453 claims |
| GSKAnoro Ellipta | $13 | $10,23618 claims |
| BayerKerendia | $278 | $10,17017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Beatrice
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.